agreement hit earn base
lower estim po agreement
yesterday american renal announc
agre settlement resolv litig involv dialysi reimburs
part settlement pay market cap five instal
start importantli expect enter three-year nation
network agreement lower guidanc
midpoint reflect agreement core guidanc intact note
abl mitig gross annual impact time
compani goe network recaptur commerci volum net
annual impact like lower highlight outstand litigation/contract
disput signific overhang stock view settlement
posit although price howev market like need see
mco dont tri follow suit understand somewhat uniqu
much network mention uniqu
larg custom payer would like fraction issu
lower estim po reflect new run rate earn impact note
commerci price remain rel stabl impact
growth trajectori new annual earn base new po
base ebitda-nci estim vs previous
reiter buy rate agreement earn reset core growth
appear track
view financi impact settlement manag pay cash
draw revolv minim impact leverag meanwhil network
agreement help work collabor regain lost commerci
volum agreement could remov uncertainti nephrologist help
develop experi value-bas care model posit compani focu
core busi growth howev market like need see plan
tri follow suit aggress price cut well look color
compani commerci price outlook come month
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
nation provid dialysi servic
compani oper dialysi clinic serv
patient chronic kidney failur also known
differenti model oper
physician partnership model partner
nephrologist develop oper dialysi
dialysi stabl recur busi
defens area health care facil
addit compani jv model help
recruit nephrologist facilit open
de novo clinic strong econom
high margin consist
shown abil take market share
consist grow top line doubl digit
po base ebitda-nci estim view uniqu
growth strong ebitda margin warrant premium multipl
growth end-stag renal diseas esrd lack altern result
above-averag demand dialysi next sever year
downsid risk manag care repres vast major profit
dialysi provid declin number insur rate pressur commerci
contract could pressur margin addit medicar rate lacklust
could regulatori scrutini compani jv structur time
kevin fischbeck cfa herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us facil hospit manag healthcar coverag cluster
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
